Susceptibilities of Simian Immunodeficiency Virus to Protease Inhibitors

Documenti analoghi

• Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1
  di: Hofman, Michael J., et al.
  Pubblicazione: (2004)
• Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase Is Selected by Tenofovir, Even in the Presence of Lamivudine
  di: Murry, Jeffrey P., et al.
  Pubblicazione: (2003)
• Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
  di: Wu, Thomas D., et al.
  Pubblicazione: (2003)
• In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors
  di: Desbois, Delphine, et al.
  Pubblicazione: (2008)
• Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1
  di: North, Thomas W., et al.
  Pubblicazione: (2005)